Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CD19/BCMA Targeted CAR T-Cells by Shanghai YaKe Biotechnology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
CD19/BCMA Targeted CAR T-Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Acute Lymphocytic...